Tissue sections including both invasive tumor and adjacent benign components from 21 breast cancer patients with high grade tumors were immunostained for K19, cyclin D1 and cyclin D3 and semiquantitatively scored for their immunoreactivity (Fig. S4, Supplementary Tables S6–8). This evidence concerns the gene KRT19 and breast cancer.